鼻アレルギーにおける血小板機能の意義:1. アレルギー性鼻炎患者におけるAzeptin投与前後の血液凝固線溶血小板機能の推移

概要

論文の詳細を見る
Azeptin, an anti-allergic drug like DSCG, Rizaben and Ketotifen, was studied to determine its usefulness in the treatment of nasal allergy. This study also clarifies the relationship between platelet function and allergic disease. Azeptin inhibits histamine release from target cells, blocks H1-receptor, and inhibits leukotriene and lipooxygenase. It was suggested that platelet-activating factor (PAF) from basophil or eosinophil aggregated the platelets and initiated release reaction from the platelets. The effect of Azeptin (Azelastin hydrochloride) to PAF was studied <I>in vitro</I>. Twenty-one patients with nasal allergy were tested for plasmin inhibitor (α2-PI) activity, antithrombin III (AT-III) activity, factor VIII (F VIII) activity, fibrinogen (Fg) contents before and after administration of Azeptin. Also, platelet function (ADP, collagen and arachidonic acid-induced aggregation) was determined. The results from this study were as follows: Azeptin most strongly inhibits PAF-induced platelet aggregation in the <I>in vitro</I> study. Some parameters in the coagulation-fibrinolysis system were not significantly different before and after administration of the drug. However, in PAF-induced platelet aggregation after the administration of Azeptin, platelet function was decreased. It was suggested that Azeptin did not affect the coagulation-fibrynolysis system, but did affect PAF-induced platelet aggregation.
耳鼻と臨床会の論文